Biogen Inc
Sector: Health Care | Industry: Biotechnology
Market Cap: $ 21 Bn
Price: $ 150
Composite Score: 57.00 (Percentile: 78.00%)
A weak moat suggests the company has limited competitive advantages, making it more susceptible to competition. It may struggle to maintain pricing power and market share in the long run.
| Metric | Value | Check |
|---|---|---|
| Net Profit Margin | 17% | ✅ |
| EPS Growth (3Y | 5Y) | 2% | 19% | ✅ |
| Revenue Growth (3Y | 5Y) | 4% | 8% | ✅ |
| Forecasted EPS Growth (5Y) | 1% | ✅ |
| Forecasted Revenue Growth (1Y) | 2% |
| Metric | Value | Check |
|---|---|---|
| ROE | 9% | ❌ |
| ROIC | 6% | ❌ |
| Debt/Equity | 0.36 | ✅ |
| Capital Allocation | Average | ❌ |
| Metric | Value | Check |
|---|---|---|
| Fair Value | 220 | ✅ |
| P/Earnings (TTM) | 14 | ✅ |
| P/Earnings Forecasted | 9 | ✅ |
| P/CashFlow | 9 | ✅ |
| PEG TTM | 14.76 | ❌ |
| Stock Buyback (5Y, 10Y) | 10%, 37% | ✅ |
The information provided on this platform is for educational and informational purposes only and does not constitute financial, investment, or trading advice. While our analysis combines Buffett-style principles with AI-driven insights, all investments involve risk, including the potential loss of capital. Past performance is not indicative of future results. You are solely responsible for your investment decisions, and we strongly encourage you to conduct your own research or consult a registered financial advisor before making any financial commitments. The content on this site is not a substitute for professional advice tailored to your personal financial situation.
INVESTMENT COMMENTARY